CORONAVIRUS RNA REPLICONS AND USE THEREOF AS VACCINES

Disclosed is an RNA replicon derived from a coronavirus having completely or partly deleted therefrom: the gene encoding the protein E and at least four genes encoding genus accessory proteins selected from: 3, 4a, 4b and 5, in the case of MERS-CoV. A method for preparing same and the use thereof in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SOLA GURPEGUI, María Isabel, ENJUANES SÁNCHEZ, Luis, ZÚÑIGA LUCAS, Sonia, GUTIÉRREZ ÁLVAREZ, Francisco Javier, HONRUBIA BELENGUER, José Manuel, FERNÁNDEZ DELGADO, Raúl
Format:	Patent
Sprache:	eng ; fre ; spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed is an RNA replicon derived from a coronavirus having completely or partly deleted therefrom: the gene encoding the protein E and at least four genes encoding genus accessory proteins selected from: 3, 4a, 4b and 5, in the case of MERS-CoV. A method for preparing same and the use thereof in vaccine compositions is also disclosed. Replicón de ARN derivado un coronavirus al que se ha delecionado total o parcialmente: el gen que codifica la proteína E y al menos 4 genes que codifican proteínas accesorias de género seleccionados entre: 3, 4a, 4b y 5, en el caso de MERS-CoV. Método de preparación del mismo, y su uso en composiciones vacunales. L'invention concerne un réplicon d'ARN dérivé d'un coronavirus auquel on a ôté une partie ou la totalité : du gène qui codifie la protéine E et au moins 4 gènes qui codifient des protéines accessoires du type sélectionnés parmi: 3, 4a, 4b et 5, dans le cas de MERS-CoV. L'invention concerne également un procédé de préparation de celui-ci, et son utilisation dans des compositions vaccinales.